title: Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.
abstract: OBJECTIVE
  In the previous COREA-TAXUS trial, a 6-month adjunctive use of celecoxib reduced target-lesion revascularization (TLR) without increased thrombotic risk. We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial.
  
  
  RESULTS
  Patients (n = 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES). In the celecoxib group, 200 mg of celecoxib was given twice daily for 3 months after the procedure. The primary endpoint was in-stent late loss (LL) at 6 months. In-stent LL was significantly lower in the celecoxib group than the control group (0.64 ± 0.54 vs. 0.55 ± 0.47 mm, P = 0.02). The trend of LL reduction in the celecoxib group was maintained in the ZES and PES subgroups, although it did not reach statistical significance. There was a trend towards the reduced clinically driven TLR in the celecoxib group (5.7 vs. 3.2%, log-rank P = 0.09), but adverse cardiac events rate did not differ between the two groups (composite of cardiac death, non-fatal myocardial infarction, and TLR; 8.6 vs. 7.7%, log-rank P = 0.84). Non-fatal myocardial infarction and cardiac death occurred in 1.6% of the patients in the celecoxib group when compared with 0.2% in the control group (log-rank P = 0.03).
  
  
  CONCLUSIONS
  Three-month adjunctive celecoxib would be useful to reduce LL of DES. However, this study may raise the concern about increased thrombotic risk with celecoxib even in patients receiving dual anti-platelet therapy.
authors.affiliation: Seoul National University Hospital, Seoul,  Republic of Korea.
authors.forename: Hyun-Jae
authors.initials: HJ
authors.lastname: Kang
authors.forename: Il-Young
authors.initials: IY
authors.lastname: Oh
authors.forename: Jin-Wook
authors.initials: JW
authors.lastname: Chung
authors.forename: Han-Mo
authors.initials: HM
authors.lastname: Yang
authors.forename: Jung-Won
authors.initials: JW
authors.lastname: Suh
authors.forename: Kyung Woo
authors.initials: KW
authors.lastname: Park
authors.forename: Taek Keun
authors.initials: TK
authors.lastname: Kwon
authors.forename: Hae-Young
authors.initials: HY
authors.lastname: Lee
authors.forename: Young-Seok
authors.initials: YS
authors.lastname: Cho
authors.forename: Tae-Jin
authors.initials: TJ
authors.lastname: Youn
authors.forename: Bon-Kwon
authors.initials: BK
authors.lastname: Koo
authors.forename: Won-Yu
authors.initials: WY
authors.lastname: Kang
authors.forename: Weon
authors.initials: W
authors.lastname: Kim
authors.forename: Seung-Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: In-Ho
authors.initials: IH
authors.lastname: Chae
authors.forename: Dong-Ju
authors.initials: DJ
authors.lastname: Choi
authors.forename: Hyo-Soo
authors.initials: HS
authors.lastname: Kim
mesh_terms: D000787:Angina Pectoris / Q000150:complications; D015906:Angioplasty, Balloon, Coronary; D050197:Atherosclerosis / Q000139:chemically induced / Q000517:prevention & control*; D001794:Blood Pressure / Q000502:physiology; D000068579:Celecoxib; D023903:Coronary Restenosis / Q000503:physiopathology / Q000517:prevention & control*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000517:prevention & control; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D058426:Neointima / Q000473:pathology*; D011446:Prospective Studies; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib